- Home
- NG vs CLDX Comparison
NG vs CLDX Comparison
Compare NG & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NG
- CLDX
- Stock Information
- Founded
- NG 1984
- CLDX N/A
- Country
- NG Canada
- CLDX United States
- Employees
- NG N/A
- CLDX N/A
- Industry
- NG Precious Metals
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- NG Basic Materials
- CLDX Health Care
- Exchange
- NG Nasdaq
- CLDX Nasdaq
- Market Cap
- NG 1.4B
- CLDX 1.3B
- IPO Year
- NG N/A
- CLDX 2008
- Fundamental
- Price
- NG $3.57
- CLDX $19.78
- Analyst Decision
- NG
- CLDX Buy
- Analyst Count
- NG 0
- CLDX 9
- Target Price
- NG N/A
- CLDX $50.00
- AVG Volume (30 Days)
- NG 5.6M
- CLDX 931.3K
- Earning Date
- NG 06-25-2025
- CLDX 05-08-2025
- Dividend Yield
- NG N/A
- CLDX N/A
- EPS Growth
- NG N/A
- CLDX N/A
- EPS
- NG N/A
- CLDX N/A
- Revenue
- NG N/A
- CLDX $7,559,000.00
- Revenue This Year
- NG N/A
- CLDX N/A
- Revenue Next Year
- NG N/A
- CLDX N/A
- P/E Ratio
- NG N/A
- CLDX N/A
- Revenue Growth
- NG N/A
- CLDX 24.49
- 52 Week Low
- NG $2.26
- CLDX $14.40
- 52 Week High
- NG $5.06
- CLDX $47.00
- Technical
- Relative Strength Index (RSI)
- NG 47.48
- CLDX 50.54
- Support Level
- NG $3.42
- CLDX $18.55
- Resistance Level
- NG $3.66
- CLDX $20.67
- Average True Range (ATR)
- NG 0.18
- CLDX 1.21
- MACD
- NG -0.03
- CLDX -0.08
- Stochastic Oscillator
- NG 48.78
- CLDX 49.25
About NG Novagold Resources Inc.
Novagold Resources Inc operates in the gold mining industry, focused on advancing the Donlin Gold project in Alaska. The Donlin Gold project is held by Donlin Gold LLC (Donlin Gold), a limited liability company owned equally by wholly owned subsidiaries of NOVAGOLD and Barrick Gold Corporation (Barrick). The company includes exploration and development activities of gold and other presious metals.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.